{"id":"arm-a-olaparib","safety":{"commonSideEffects":[{"rate":"30-40%","effect":"Nausea"},{"rate":"20-30%","effect":"Vomiting"},{"rate":"20-30%","effect":"Fatigue"},{"rate":"10-20%","effect":"Anemia"},{"rate":"10-20%","effect":"Thrombocytopenia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By inhibiting PARP1, olaparib causes DNA damage in cancer cells, leading to cell death. This mechanism is particularly effective in cancers with BRCA1 or BRCA2 mutations, which are defective in DNA repair.","oneSentence":"Olaparib is a PARP inhibitor that blocks the enzyme PARP1, preventing cancer cells from repairing DNA damage.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T02:29:17.693Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Maintenance treatment of platinum-sensitive relapsed ovarian cancer"},{"name":"Maintenance treatment of platinum-sensitive relapsed, BRCA mutated, advanced ovarian cancer"}]},"trialDetails":[{"nctId":"NCT07024784","phase":"PHASE2","title":"A Study to Assess Change in Disease Activity and Adverse Events in Adult Participants With Gynecologic Cancers Receiving Intravenous Infusion of IMGN151 as Monotherapy or in Combination With Other Therapies","status":"RECRUITING","sponsor":"AbbVie","startDate":"2025-07-30","conditions":"Gynecologic Cancers, Platinum-Sensitive Ovarian Cancer, Fallopian Tube Cancer","enrollment":377},{"nctId":"NCT05564377","phase":"PHASE2","title":"Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2023-04-07","conditions":"Advanced Malignant Solid Neoplasm, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8","enrollment":2900},{"nctId":"NCT02893917","phase":"PHASE2","title":"Testing Two Oral Drugs Combination (Cediranib and Olaparib) Compared to a Single Drug (Olaparib) for Men With Advanced Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2017-08-11","conditions":"Advanced Prostate Adenocarcinoma With Neuroendocrine Differentiation, Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma With Neuroendocrine Differentiation","enrollment":90},{"nctId":"NCT03297606","phase":"PHASE2","title":"Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR)","status":"RECRUITING","sponsor":"Canadian Cancer Trials Group","startDate":"2018-03-23","conditions":"Lymphoma, Non-Hodgkin, Multiple Myeloma, Advanced Solid Tumors","enrollment":720},{"nctId":"NCT04548752","phase":"PHASE2","title":"Testing the Addition of Pembrolizumab, an Immunotherapy Cancer Drug to Olaparib Alone as Therapy for Patients With Pancreatic Cancer That Has Spread With Inherited BRCA Mutations","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-02-22","conditions":"Metastatic Pancreatic Adenocarcinoma, Stage IV Pancreatic Cancer AJCC v8","enrollment":88},{"nctId":"NCT04858334","phase":"PHASE2","title":"APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-06-22","conditions":"Pancreatic Acinar Cell Carcinoma, Pancreatic Adenosquamous Carcinoma, Pancreatic Squamous Cell Carcinoma","enrollment":152},{"nctId":"NCT05554328","phase":"PHASE2","title":"Testing the Use of the Combination of Selumetinib and Olaparib or Selumetinib Alone Targeted Treatment for RAS Pathway Mutant Recurrent or Persistent Ovarian and Endometrial Cancers, A ComboMATCH Treatment Trial","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2023-04-25","conditions":"Recurrent Endometrial Carcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma","enrollment":165},{"nctId":"NCT04034927","phase":"PHASE2","title":"Testing the Addition of an Immunotherapy Drug, Tremelimumab, to the PARP Inhibition Drug, Olaparib, for Recurrent Ovarian, Fallopian Tube or Peritoneal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2019-12-04","conditions":"Fallopian Tube Endometrioid Tumor, Fallopian Tube High Grade Serous Adenocarcinoma, Malignant Ovarian Endometrioid Tumor","enrollment":61},{"nctId":"NCT04394858","phase":"PHASE2","title":"Testing the Addition of an Anticancer Drug, Olaparib, to the Usual Chemotherapy (Temozolomide) for Advanced Neuroendocrine Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-03-17","conditions":"Advanced Adrenal Gland Pheochromocytoma, Advanced Paraganglioma, Metastatic Adrenal Gland Pheochromocytoma","enrollment":46},{"nctId":"NCT06580314","phase":"PHASE3","title":"Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer","status":"RECRUITING","sponsor":"NRG Oncology","startDate":"2025-03-12","conditions":"Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube High Grade Serous Adenocarcinoma, FIGO Stage III Ovarian Cancer 2014","enrollment":880},{"nctId":"NCT06353386","phase":"PHASE1, PHASE2","title":"Substudy 01A: Safety and Efficacy of Opevesostat (MK-5684)-Based Treatment Combinations or Opevesostat Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-01A)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2024-05-20","conditions":"Prostatic Neoplasms, Castration-Resistant","enrollment":220},{"nctId":"NCT06915025","phase":"PHASE3","title":"Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemotherapy in Newly Diagnosed Patients w/ Advanced EOC, Fallopian Tube or Primary Peritoneal Cancer","status":"RECRUITING","sponsor":"Imunon","startDate":"2025-07-09","conditions":"Epithelial Ovarian Cancer, Ovarian Cancer, Fallopian Tube Cancer","enrollment":500},{"nctId":"NCT07475923","phase":"","title":"Molecular Surveillance In Early Breast Cancer Using The Tumor-Informed ctDNA Assay Myriad Genetics Precise MRD Test; A Prospective Observational Multicenter Study (The MRD Molecular Surveillance Study)","status":"NOT_YET_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2026-08-26","conditions":"Molecular Surveillance, Breast Cancer, ctDNA","enrollment":300},{"nctId":"NCT06797635","phase":"PHASE2","title":"Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-03-20","conditions":"Breast Neoplasms, Breast Cancer","enrollment":372},{"nctId":"NCT01042379","phase":"PHASE2","title":"I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer","status":"RECRUITING","sponsor":"QuantumLeap Healthcare Collaborative","startDate":"2010-03-01","conditions":"Breast Neoplasms, Breast Cancer, Breast Tumors","enrollment":5000},{"nctId":"NCT07018622","phase":"PHASE2","title":"Protecting the Kidney's Proximal Tubules From Platinum-Based Chemotherapy Toxicity","status":"RECRUITING","sponsor":"Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran","startDate":"2025-05-07","conditions":"Solid Tumors, Cisplatin Nephrotoxicity","enrollment":46},{"nctId":"NCT04931342","phase":"PHASE2","title":"A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2021-10-07","conditions":"Ovarian Cancer","enrollment":176},{"nctId":"NCT03330847","phase":"PHASE2","title":"To Assess Safety and Efficacy of Agents Targeting DNA Damage Repair With Olaparib Versus Olaparib Monotherapy.","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2018-03-07","conditions":"Metastatic Triple Negative Breast Cancer","enrollment":273},{"nctId":"NCT03660826","phase":"PHASE2","title":"Testing the Combination of Olaparib and Durvalumab, Cediranib and Durvalumab, Olaparib and Capivasertib, and Cediranib Alone in Recurrent or Refractory Endometrial Cancer Following the Earlier Phase of the Study That Tested Olaparib and Cediranib in Comparison to Cediranib Alone, and Olaparib Alone","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2018-09-27","conditions":"Endometrial Adenocarcinoma, Endometrial Mixed Cell Adenocarcinoma, Endometrial Serous Adenocarcinoma","enrollment":288},{"nctId":"NCT04748042","phase":"PHASE2","title":"Focal Radiation With Pulsed Systemic Therapy of Abiraterone, Androgen Deprivation Therapy (ADT), Lynparza Towards Castration Sensitive Oligometastatic Prostate Cancer (FAALCON)","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Michigan Rogel Cancer Center","startDate":"2021-05-28","conditions":"Prostate Cancer, Castrate Sensitive Prostate Cancer, Oligometastatic Disease","enrollment":21},{"nctId":"NCT07454018","phase":"PHASE2","title":"Iparomlimab/Tuvonralimab + Standard Chemotherapy and Olaparib in Platinum-Sensitive Recurrent Ovarian Cancer","status":"NOT_YET_RECRUITING","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2026-03-01","conditions":"Recurrent Ovarian Cancer, Platinum-sensitive Ovarian Cancer","enrollment":45},{"nctId":"NCT02446600","phase":"PHASE3","title":"Testing the Use of A Single Drug (Olaparib) or the Combination of Two Drugs (Cediranib and Olaparib) Compared to the Usual Chemotherapy for Women With Platinum Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2016-03-28","conditions":"Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Transitional Cell Carcinoma, Fallopian Tube Undifferentiated Carcinoma","enrollment":579},{"nctId":"NCT02502266","phase":"PHASE2, PHASE3","title":"Testing the Combination of Cediranib and Olaparib in Comparison to Each Drug Alone or Other Chemotherapy in Recurrent Platinum-Resistant Ovarian Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2016-05-03","conditions":"Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube Serous Adenocarcinoma","enrollment":582},{"nctId":"NCT01116648","phase":"PHASE1, PHASE2","title":"Cediranib Maleate and Olaparib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Peritoneal Cancer or Recurrent Triple-Negative Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2010-04-14","conditions":"Fallopian Tube Carcinoma, Ovarian Endometrioid Adenocarcinoma, Ovarian High Grade Serous Adenocarcinoma","enrollment":155},{"nctId":"NCT04739800","phase":"PHASE2","title":"Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-06-10","conditions":"Fallopian Tube Mucinous Adenocarcinoma, Ovarian Seromucinous Carcinoma, Platinum-Refractory Fallopian Tube Carcinoma","enrollment":120},{"nctId":"NCT05463848","phase":"PHASE2","title":"Surgical Pembro +/- Olaparib w TMZ for rGBM","status":"RECRUITING","sponsor":"L. Nicolas Gonzalez Castro, MD, PhD","startDate":"2022-10-21","conditions":"Glioblastoma, Recurrent Glioblastoma","enrollment":78},{"nctId":"NCT04005690","phase":"EARLY_PHASE1","title":"Targeted Pathway Inhibition in Patients With Pancreatic Cancer","status":"RECRUITING","sponsor":"OHSU Knight Cancer Institute","startDate":"2019-08-01","conditions":"Locally Advanced Pancreatic Ductal Adenocarcinoma, Metastatic Pancreatic Ductal Adenocarcinoma, Stage II Pancreatic Cancer AJCC v8","enrollment":90},{"nctId":"NCT03801369","phase":"PHASE2","title":"AMTEC IIT: Phase 2 Multiarm Study in TNBC","status":"TERMINATED","sponsor":"Gordon Mills, MD, PhD","startDate":"2018-12-12","conditions":"Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Triple-Negative Breast Carcinoma","enrollment":24},{"nctId":"NCT03317392","phase":"PHASE1, PHASE2","title":"Testing the Safety of Different Doses of Olaparib Given Radium-223 for Men With Advanced Prostate Cancer With Bone Metastasis","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2019-02-04","conditions":"Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8","enrollment":145},{"nctId":"NCT03579316","phase":"PHASE2","title":"Adavosertib With or Without Olaparib in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2018-12-07","conditions":"Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma","enrollment":96},{"nctId":"NCT04683679","phase":"PHASE2","title":"A Study of Radiation Therapy With Pembrolizumab and Olaparib or Other Radiosensitizers in Women Who Have Triple-Negative or Hormone-Receptor Positive/Her2 Negative Breast Cancer","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2021-04-21","conditions":"Triple Negative Breast Cancer, TNBC - Triple-Negative Breast Cancer, Breast Cancer","enrollment":34},{"nctId":"NCT02861573","phase":"PHASE1, PHASE2","title":"Study of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (MK-3475-365/KEYNOTE-365)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2016-11-17","conditions":"Metastatic Castration-Resistant Prostate Cancer","enrollment":1200},{"nctId":"NCT06135714","phase":"PHASE3","title":"Metastasis-directed Therapy for Oligometastases of Breast Cancer","status":"RECRUITING","sponsor":"Tokyo Medical and Dental University","startDate":"2023-11-08","conditions":"Breast Cancer, Oligometastasis, Metastatic Breast Cancer","enrollment":340},{"nctId":"NCT03025035","phase":"PHASE2","title":"Pembrolizumab in Combination With Olaparib in Advanced BRCA-mutated or HDR-defect Breast Cancer","status":"COMPLETED","sponsor":"Yuan Yuan","startDate":"2017-09-10","conditions":"Breast Cancer","enrollment":14},{"nctId":"NCT05432791","phase":"PHASE2, PHASE3","title":"Testing Olaparib and Temozolomide Versus the Usual Treatment for Uterine Leiomyosarcoma After Chemotherapy Has Stopped Working","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2023-03-30","conditions":"Locally Advanced Uterine Corpus Leiomyosarcoma, Metastatic Uterine Corpus Leiomyosarcoma, Stage III Uterine Corpus Leiomyosarcoma AJCC v8","enrollment":73},{"nctId":"NCT05568550","phase":"PHASE2","title":"Pembro With Radiation With or Without Olaparib","status":"RECRUITING","sponsor":"Zin W Myint","startDate":"2023-07-27","conditions":"Prostate Cancer","enrollment":64},{"nctId":"NCT03459846","phase":"PHASE2","title":"A Study of Durvalumab Alone and Durvalumab+Olaparib in Advanced, Platinum-Ineligible Bladder Cancer (BAYOU)","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2018-03-16","conditions":"Urinary Bladder Neoplasms","enrollment":154},{"nctId":"NCT02734004","phase":"PHASE1, PHASE2","title":"A Phase I/II Study of MEDI4736 in Combination With Olaparib in Patients With Advanced Solid Tumors.","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2016-03-17","conditions":"Ovarian, Breast, SCLC","enrollment":264},{"nctId":"NCT05366166","phase":"PHASE2","title":"Pembrolizumab Plus Olaparib in LA-HNSCC","status":"ACTIVE_NOT_RECRUITING","sponsor":"UNC Lineberger Comprehensive Cancer Center","startDate":"2022-09-02","conditions":"Squamous Cell Carcinoma of Head and Neck","enrollment":45},{"nctId":"NCT06746116","phase":"PHASE3","title":"A Study to Evaluate the Use of Durvalumab in Combination With Platinum-based Chemotherapy Followed by Durvalumab With Olaparib as First-line Treatment in Advanced or Recurrent Endometrial Cancer in Spain","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2024-12-30","conditions":"Advanced or Recurrent Endometrial Cancer","enrollment":45},{"nctId":"NCT02813135","phase":"PHASE1, PHASE2","title":"European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors","status":"RECRUITING","sponsor":"Gustave Roussy, Cancer Campus, Grand Paris","startDate":"2016-08-03","conditions":"Pediatric Cancer","enrollment":472},{"nctId":"NCT05826964","phase":"PHASE2","title":"Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Miami","startDate":"2023-06-12","conditions":"Breast Cancer, ER-positive Breast Cancer, HER2-negative Breast Cancer","enrollment":24},{"nctId":"NCT03923270","phase":"PHASE1","title":"Radiotherapy and Durvalumab/Durvalumab Combo (Tremelimumab/Olaparid) for Small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2019-06-06","conditions":"Small Cell Lung Cancer Extensive Stage, Small-cell Lung Cancer","enrollment":25},{"nctId":"NCT06630325","phase":"PHASE2","title":"A Precision Medicine Approach (SMMART-ACT) for the Treatment of Patients With Advanced Sarcoma, Prostate, Breast, Ovarian or Pancreatic Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"OHSU Knight Cancer Institute","startDate":"2025-06-24","conditions":"Advanced Breast Carcinoma, Advanced Malignant Solid Neoplasm, Advanced Ovarian Carcinoma","enrollment":30},{"nctId":"NCT02208375","phase":"PHASE1","title":"mTORC1/2 Inhibitor AZD2014 or the Oral AKT Inhibitor AZD5363 for Recurrent Endometrial and Ovarian","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2014-11-11","conditions":"BRCA1 Mutation Carrier, BRCA2 Mutation Carrier, Endometrial Adenocarcinoma","enrollment":159},{"nctId":"NCT02546661","phase":"PHASE1","title":"Open-Label, Randomised, Multi-Drug, Biomarker-Directed, Phase 1b Study in Pts w/ Muscle Invasive Bladder Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2016-12-28","conditions":"Muscle Invasive Bladder Cancer","enrollment":117},{"nctId":"NCT06545942","phase":"PHASE1","title":"Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors","status":"RECRUITING","sponsor":"MOMA Therapeutics","startDate":"2024-08-13","conditions":"Advanced Solid Tumor, Metastatic Solid Tumor, Prostate Cancer","enrollment":220},{"nctId":"NCT04269200","phase":"PHASE3","title":"Durvalumab With or Without Olaparib as Maintenance Therapy After First-Line Treatment of Advanced and Recurrent Endometrial Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2020-05-05","conditions":"Endometrial Neoplasms","enrollment":805},{"nctId":"NCT04550104","phase":"PHASE1","title":"A Platform Study of Novel Agents in Combination With Radiotherapy in NSCLC","status":"RECRUITING","sponsor":"University of Leeds","startDate":"2021-03-17","conditions":"Non Small Cell Lung Cancer","enrollment":200},{"nctId":"NCT05240898","phase":"PHASE1","title":"A Phase 1 Study of RO7623066 Alone and in Combination in Patients With Advanced Solid Tumors","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2021-08-26","conditions":"Advanced Solid Tumors","enrollment":116},{"nctId":"NCT05128734","phase":"PHASE2","title":"Temozolomide Monotherapy or in Combination With Olaparib in Patients With Triple Negative Breast Cancer (TNBC)","status":"NOT_YET_RECRUITING","sponsor":"AHS Cancer Control Alberta","startDate":"2026-04-01","conditions":"Breast Cancer Triple Negative","enrollment":40},{"nctId":"NCT03784014","phase":"PHASE3","title":"Molecular Profiling of Advanced Soft-tissue Sarcomas","status":"ACTIVE_NOT_RECRUITING","sponsor":"Institut National de la Santé Et de la Recherche Médicale, France","startDate":"2019-10-19","conditions":"Soft Tissue Sarcoma","enrollment":603},{"nctId":"NCT05522491","phase":"PHASE2","title":"Olaparib in the Treatment of BRCA1/2 Unmutated and BRCA1 Promoter Methylated Recurrent and Metastatic Triple-negative Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"Hebei Medical University Fourth Hospital","startDate":"2026-09-01","conditions":"Solid Tumor","enrollment":30},{"nctId":"NCT07268794","phase":"PHASE2","title":"CONVERT-HB1: Radical Prostatectomy After Systemic Therapy for High-volume Metastatic Hormone-sensitive Prostate Cancer","status":"NOT_YET_RECRUITING","sponsor":"Fudan University","startDate":"2025-11-30","conditions":"Metastatic Prostate Cancer, Prostate Cancer (Adenocarcinoma), Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)","enrollment":112},{"nctId":"NCT05568212","phase":"PHASE2","title":"Randomized Trial Comparing Standard of Care Versus Immune- Based Combination in Relapsed Stage III Non-small-cell Lung Cancer (NSCLC) Pretreated With Chemoradiotherapy and Durvalumab","status":"RECRUITING","sponsor":"Fondazione Ricerca Traslazionale","startDate":"2022-05-02","conditions":"Non-small-cell Lung Cancer Patients","enrollment":176},{"nctId":"NCT06201234","phase":"PHASE2","title":"Evaluating the Addition of Elacestrant (Oral SERD) to Olaparib (PARP-inhibitor) in Patients With Advanced/Metastatic HR+/HER2- Breast Cancer","status":"RECRUITING","sponsor":"GBG Forschungs GmbH","startDate":"2024-12-13","conditions":"Hormone Receptor Positive HER-2 Negative Breast Cancer, Advanced or Metastatic Breast Cancer, BRCA1 Mutation","enrollment":176},{"nctId":"NCT06116578","phase":"PHASE2","title":"Study Evaluating Pembrolizumab +/- Olaparib in TLS Positive Selected Resectable STS Followed by Adjuvant Pembrolizumab","status":"WITHDRAWN","sponsor":"Gustave Roussy, Cancer Campus, Grand Paris","startDate":"2025-01-01","conditions":"Cancer","enrollment":""},{"nctId":"NCT02849496","phase":"PHASE2","title":"Testing Olaparib Either Alone or in Combination With Atezolizumab in BRCA Mutant Non-HER2-positive Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2017-03-30","conditions":"Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Locally Advanced Unresectable Breast Carcinoma","enrollment":81},{"nctId":"NCT05252390","phase":"PHASE1","title":"NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors","status":"TERMINATED","sponsor":"Nuvation Bio Inc.","startDate":"2022-03-29","conditions":"Advanced Solid Tumor, Ovarian Cancer, Ovary Cancer","enrollment":82},{"nctId":"NCT03334617","phase":"PHASE2","title":"Phase II Umbrella Study of Novel Anti-cancer Agents in Participants With NSCLC Who Progressed on an Anti-PD-1/PD-L1 Containing Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2017-12-18","conditions":"Non-Small Cell Lung Cancer","enrollment":528},{"nctId":"NCT04643379","phase":"PHASE2","title":"Olaparib in Combination With Pembrolizumab and Carboplatin as First-Line Treatment of Recurrent or Metastatic Head and Neck Squamous-Cell Carcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2021-08-07","conditions":"Recurrent Head and Neck Squamous Cell Carcinoma, Metastatic Head and Neck Squamous Cell Carcinoma","enrollment":30},{"nctId":"NCT03012321","phase":"PHASE2","title":"Abiraterone/Prednisone, Olaparib, or Abiraterone/Prednisone + Olaparib in Patients With Metastatic Castration-Resistant Prostate Cancer With DNA Repair Defects","status":"ACTIVE_NOT_RECRUITING","sponsor":"Northwestern University","startDate":"2017-01-12","conditions":"Prostate Cancer Metastatic Castration-Resistant, Abnormal DNA Repair, Metastatic Prostate Carcinoma","enrollment":70},{"nctId":"NCT04038502","phase":"PHASE2","title":"Carboplatin or Olaparib for BRcA Deficient Prostate Cancer","status":"RECRUITING","sponsor":"VA Office of Research and Development","startDate":"2019-10-01","conditions":"Metastatic Castrate Resistant Prostate Cancer, BARD1, BRCA1, BRCA2, BRIP1, CHEK1, FANCL, PALB2, RAD51B, RAD51C, RAD51D, or RAD54L Mutations","enrollment":100},{"nctId":"NCT06401980","phase":"PHASE2","title":"Darolutamide in Metastatic Castration-Resistant Prostate Cancer (mCRPC)","status":"RECRUITING","sponsor":"Swiss Cancer Institute","startDate":"2024-10-22","conditions":"Metastatic Castration-resistant Prostate Cancer","enrollment":162},{"nctId":"NCT03740893","phase":"PHASE2","title":"PHOENIX DDR/Anti-PD-L1 Trial: A Pre-surgical Window of Opportunity and Post-surgical Adjuvant Biomarker Study of DNA Damage Response Inhibition With or Without Anti-PD-L1 Immunotherapy in Patients With Neoadjuvant Treatment Resistant Residual Triple Negative Breast Cancer","status":"RECRUITING","sponsor":"Institute of Cancer Research, United Kingdom","startDate":"2019-10-15","conditions":"Breast Neoplasm, Triple Negative Breast Cancer (TNBC), HRD","enrollment":119},{"nctId":"NCT07113964","phase":"PHASE2","title":"QL1706 With Olaparib for Previously Treated HER2-negative Breast Cancer Patients With Homologous Recombination Deficiency (HRD)","status":"NOT_YET_RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2025-08-30","conditions":"Previously Treated HER2-negative Breast Cancer Patients With Homologous Recombination Deficiency","enrollment":79},{"nctId":"NCT02029001","phase":"PHASE2","title":"Adapting Treatment to the Tumor Molecular Alterations for Patients With Advanced Solid Tumors: MyOwnSpecificTreatment","status":"RECRUITING","sponsor":"Centre Leon Berard","startDate":"2014-03","conditions":"Malignant Solid Neoplasms","enrollment":900},{"nctId":"NCT02974621","phase":"PHASE2","title":"Cediranib Maleate and Olaparib Compared to Bevacizumab in Treating Patients With Recurrent Glioblastoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2017-12-07","conditions":"Recurrent Glioblastoma","enrollment":70},{"nctId":"NCT04348045","phase":"PHASE2","title":"Maintenance With Olaparib or Selumetinib + Durvaluma for m-PDAC Guided by BRCAness and KRAS Status.","status":"ACTIVE_NOT_RECRUITING","sponsor":"GERCOR - Multidisciplinary Oncology Cooperative Group","startDate":"2020-12-07","conditions":"Metastatic Pancreatic Adenocarcinoma","enrollment":307},{"nctId":"NCT05005728","phase":"PHASE2","title":"XmAb®20717 (Vudalimab) Alone or in Combination With Chemotherapy or Targeted Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer","status":"COMPLETED","sponsor":"Xencor, Inc.","startDate":"2021-10-22","conditions":"Metastatic Castration-Resistant Prostate Cancer","enrollment":72},{"nctId":"NCT04592211","phase":"PHASE1, PHASE2","title":"Pembrolizumab, Olaparib, Recurrent/Advanced Gastric and Gastro-esophageal Junction(GEJ) Cancer","status":"RECRUITING","sponsor":"Yonsei University","startDate":"2021-10-01","conditions":"Gastric Cancer Stage IV","enrollment":71},{"nctId":"NCT03682289","phase":"PHASE2","title":"Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors","status":"RECRUITING","sponsor":"Rahul Aggarwal","startDate":"2019-01-17","conditions":"Clear Cell Renal Cell Carcinoma, Locally Advanced Pancreatic Cancer, Locally Advanced Malignant Solid Neoplasm","enrollment":89},{"nctId":"NCT02419495","phase":"PHASE1","title":"Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies","status":"TERMINATED","sponsor":"M.D. Anderson Cancer Center","startDate":"2015-06-26","conditions":"Advanced Malignant Solid Neoplasm, Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8","enrollment":221},{"nctId":"NCT02571725","phase":"PHASE1, PHASE2","title":"PARP-inhibition and CTLA-4 Blockade in BRCA-deficient Ovarian Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"New Mexico Cancer Research Alliance","startDate":"2016-02-23","conditions":"Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Neoplasms","enrollment":50},{"nctId":"NCT04515836","phase":"PHASE2","title":"Olaparib in Patients With HRD Malignant Mesothelioma","status":"RECRUITING","sponsor":"University of Chicago","startDate":"2021-02-19","conditions":"Mesothelioma, Homologous Recombination Deficiency","enrollment":56},{"nctId":"NCT06643585","phase":"PHASE3","title":"A Randomized Secondary Adjuvant Treatment Intervention Study Comparing Trastuzumab-Deruxtecan to SOC Therapy in eBC Patients With Molecular Relapse","status":"RECRUITING","sponsor":"Prof. Wolfgang Janni","startDate":"2025-04-22","conditions":"Breast Cancer","enrollment":180},{"nctId":"NCT05332561","phase":"PHASE2","title":"Genomics Guided Targeted Post-neoadjuvant Therapy in Patients With Early Breast Cancer (COGNITION-GUIDE)","status":"RECRUITING","sponsor":"German Cancer Research Center","startDate":"2023-06-29","conditions":"Early-stage Breast Cancer","enrollment":240},{"nctId":"NCT04330040","phase":"PHASE4","title":"Prospective Multicentre Phase-IV Clinical Trial of Olaparib in Indian Patients With Ovarian and Metastatic Breast Cancer","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2020-05-25","conditions":"Ovarian Cancer, Breast Cancer","enrollment":202},{"nctId":"NCT04614909","phase":"EARLY_PHASE1","title":"Study of Pamiparib in Newly Diagnosed and rGBM","status":"ACTIVE_NOT_RECRUITING","sponsor":"Nader Sanai","startDate":"2021-01-11","conditions":"Glioblastoma, Glioblastoma Multiforme, Glioblastoma Multiforme, Adult","enrollment":45},{"nctId":"NCT04306367","phase":"PHASE2","title":"Study of Pembrolizumab and Olaparib in Bile Duct Cancer","status":"COMPLETED","sponsor":"Georgetown University","startDate":"2020-04-01","conditions":"Cholangiocarcinoma","enrollment":14},{"nctId":"NCT03737643","phase":"PHASE3","title":"Durvalumab Treatment in Combination With Chemotherapy and Bevacizumab, Followed by Maintenance Durvalumab, Bevacizumab and Olaparib Treatment in Advanced Ovarian Cancer Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2019-01-04","conditions":"Advanced Ovarian Cancer","enrollment":1407},{"nctId":"NCT04538378","phase":"PHASE2","title":"Olaparib (LYNPARZA) Plus Durvalumab (IMFINZI) in EGFR-Mutated Adenocarcinomas That Transform to Small Cell Lung Cancer (SCLC) and Other Neuroendocrine Tumors","status":"TERMINATED","sponsor":"National Cancer Institute (NCI)","startDate":"2021-07-07","conditions":"EGFR-Mutated Non-Small-Cell Lung Carcinoma, Small Cell/Neuroendocrine","enrollment":4},{"nctId":"NCT02299999","phase":"PHASE2","title":"SAFIR02_Breast - Efficacy of Genome Analysis as a Therapeutic Decision Tool for Patients With Metastatic Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"UNICANCER","startDate":"2014-04-07","conditions":"Metastatic Breast Cancer","enrollment":1460},{"nctId":"NCT03314740","phase":"PHASE2","title":"Best Approach in Recurrent-Ovarian-Cancer-with Cediranib-Olaparib","status":"COMPLETED","sponsor":"Mario Negri Institute for Pharmacological Research","startDate":"2017-06-12","conditions":"Ovarian Neoplasms","enrollment":123},{"nctId":"NCT03745950","phase":"PHASE2","title":"UTOLA: UTerin OLAparib","status":"COMPLETED","sponsor":"ARCAGY/ GINECO GROUP","startDate":"2019-02-01","conditions":"Endometrial Carcinoma","enrollment":147},{"nctId":"NCT03838744","phase":"PHASE2","title":"Randomized Trial in Advanced, Metastatic or Unresectable Soft Tissue Sarcoma After Failure of Standard Treatments.","status":"COMPLETED","sponsor":"Italian Sarcoma Group","startDate":"2020-05-20","conditions":"Advanced Soft Tissue Sarcoma","enrollment":130},{"nctId":"NCT06437353","phase":"PHASE2","title":"Surufatinib Combined With Carboplatin/Paclitaxel and Surufatinib Combined With Olaparib as First-line and Maintenance Therapy for Newly Diagnosed High-risk Ovarian Cancer","status":"RECRUITING","sponsor":"Anhui Provincial Cancer Hospital","startDate":"2024-05-25","conditions":"Ovarian Cancer","enrollment":74},{"nctId":"NCT06607692","phase":"PHASE2","title":"Study in Children and Adolescents of 177Lu-DOTATATE (Lutathera®) Combined with the PARP Inhibitor Olaparib for the Treatment of Recurrent or Relapsed Solid Tumours Expressing Somatostatin Receptor (SSTR) (LuPARPed).","status":"RECRUITING","sponsor":"Fundación de investigación HM","startDate":"2024-10","conditions":"Solid Tumor Cancer, Medulloblastoma, High Risk Neuroblastoma","enrollment":25},{"nctId":"NCT06585007","phase":"PHASE3","title":"Metastasis-directed Therapy in Oligoprogressive Castration-refractory Prostate Cancer","status":"RECRUITING","sponsor":"Universitaire Ziekenhuizen KU Leuven","startDate":"2023-12-19","conditions":"Castration-resistant Prostate Cancer, Oligoprogressive","enrollment":246},{"nctId":"NCT03402841","phase":"PHASE3","title":"Multicentre Study of Olaparib Maintenance Monotherapy in Platinum Sensitive Relapsed Non gBRCAm Ovarian Cancer Patients","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2018-01-30","conditions":"Non-Germline BRCA Mutated Ovarian Cancer","enrollment":279},{"nctId":"NCT02937818","phase":"PHASE2","title":"A Phase II, Study to Determine the Preliminary Efficacy of Novel Combinations of Treatment in Patients With Platinum Refractory Extensive-Stage Small-Cell Lung Cancer","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2016-11-28","conditions":"Platinum Refractory Extensive-Stage Small Cell Lung Carcinoma","enrollment":72},{"nctId":"NCT06377267","phase":"PHASE2","title":"Status of HRD That Lead to a Benefit From Olaparib in Combination With Bevacizumab (STROBE Trial)","status":"RECRUITING","sponsor":"Vall d'Hebron Institute of Oncology","startDate":"2024-02-06","conditions":"Ovarian Cancer","enrollment":100},{"nctId":"NCT03127215","phase":"PHASE2","title":"Study of Olaparib/Trabectedin vs. Doctor's Choice in Solid Tumors","status":"COMPLETED","sponsor":"National Center for Tumor Diseases, Heidelberg","startDate":"2018-10-25","conditions":"Cancers With DNA Repair-Deficiency","enrollment":102},{"nctId":"NCT05967286","phase":"PHASE2","title":"Olaparib and Alpelisib for Treatment of Metastatic Breast Cancer, A ComboMATCH Treatment Trial","status":"WITHDRAWN","sponsor":"National Cancer Institute (NCI)","startDate":"2023-10-23","conditions":"Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Metastatic HER2-Negative Breast Carcinoma","enrollment":""},{"nctId":"NCT00494234","phase":"PHASE2","title":"Study to Assess The Efficacy and Safety of a PARP Inhibitor For The Treatment of BRCA-positive Advanced Breast Cancer","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2007-06-15","conditions":"Breast Neoplasms","enrollment":54},{"nctId":"NCT02117167","phase":"PHASE2","title":"SAFIR02_Lung - Efficacy of Targeted Drugs Guided by Genomic Profiles in Metastatic NSCLC Patients","status":"COMPLETED","sponsor":"UNICANCER","startDate":"2014-04-23","conditions":"Non-small Cell Lung Cancer Metastatic","enrollment":999},{"nctId":"NCT02503436","phase":"","title":"C-PATROL - Non-interventional Study (NIS) to Collect Clinical and Patient Reported Outcome Data in an Olaparib Treated BRCAm+ PSR Ovarian Cancer Population","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2015-10-28","conditions":"Ovarian Cancer, Hereditary Ovarian Cancer Syndrome","enrollment":276},{"nctId":"NCT02899728","phase":"PHASE2","title":"Olaparib, Cediranib Maleate, and Standard Chemotherapy in Treating Patients With Small Cell Lung Cancer","status":"TERMINATED","sponsor":"National Cancer Institute (NCI)","startDate":"2018-03-30","conditions":"Extensive Stage Lung Small Cell Carcinoma","enrollment":9},{"nctId":"NCT05295589","phase":"PHASE2","title":"Comparing Standard of Care Chemotherapy Treatment to the Combination of Copanlisib and Olaparib for Recurrent Platinum Resistant Ovarian Cancer That Has Progressed Through PARP Inhibitor Therapy","status":"WITHDRAWN","sponsor":"National Cancer Institute (NCI)","startDate":"2022-06-30","conditions":"Platinum-Refractory Fallopian Tube Carcinoma, Platinum-Refractory Ovarian Carcinoma, Platinum-Refractory Primary Peritoneal Carcinoma","enrollment":""},{"nctId":"NCT05411679","phase":"PHASE2","title":"EP0057 in Combination With Olaparib in Relapsed Advanced Gastric Cancer and Small Cell Lung Cancer","status":"WITHDRAWN","sponsor":"Ellipses Pharma","startDate":"2023-04","conditions":"Gastric Cancer, Small-cell Lung Cancer","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["AZD-2281"],"phase":"phase_2","status":"active","brandName":"Arm A - Olaparib","genericName":"Arm A - Olaparib","companyName":"GERCOR - Multidisciplinary Oncology Cooperative Group","companyId":"gercor-multidisciplinary-oncology-cooperative-group","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Olaparib is a PARP inhibitor that blocks the enzyme PARP1, preventing cancer cells from repairing DNA damage. Used for Maintenance treatment of platinum-sensitive relapsed ovarian cancer, Maintenance treatment of platinum-sensitive relapsed, BRCA mutated, advanced ovarian cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}